Presentation is loading. Please wait.

Presentation is loading. Please wait.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated."— Presentation transcript:

1 The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment.
The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. A, a representative mouse with 2 HCT116 flank tumor xenografts. The left tumor (black arrow) was injected with STM1787 pPROMOTERLux-expressing Salmonella, whereas the right tumor (red arrow) was injected with constitutive pMAAC001-expressing Salmonella, and the mouse imaged at the indicated times postinjection. B, the mean photon flux for each set of Salmonella-injected tumors, normalized to the initial signal in each tumor, and plotted as a function of time. Error bars represent SEM; pPROMOTERLux (n = 6); pLux (n = 3); pMAAC001 (n = 3). *, P < Kelly Flentie et al. Cancer Discovery 2012;2: ©2012 by American Association for Cancer Research

Download ppt "The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated."

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

AF647-RIS is internalized by TAMs in vivo.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Cell signaling and cancer

Cell signaling and cancer
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
 Design and use of a high-throughput screen to identify tumor cell-induced gene activation events in Salmonella.  Design and use of a high-throughput screen.

 Design and use of a high-throughput screen to identify tumor cell-induced gene activation events in Salmonella.  Design and use of a high-throughput screen.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Acute, systemic Atg7 deficiency compromises tumorigenesis.

Acute, systemic Atg7 deficiency compromises tumorigenesis.
LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.
HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.
Deficiency of Cdkn2a leads to aberrant activation of RhoA in vivo.

Deficiency of Cdkn2a leads to aberrant activation of RhoA in vivo.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.
Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Similar presentations

Ads by Google